Bronchiolitis obliterans after stem-cell transplant: causes and new treatments
Bronchiolitis Obliterans: Discovery and Therapy
This project tries a new drug called KD025 (a ROCK2 blocker) to help people who develop bronchiolitis obliterans after an allogeneic stem-cell transplant.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11174489 on NIH RePORTER |
What this research studies
You would be offered a clinical treatment with KD025 aimed at the lung problems that happen after an allogeneic transplant. At the same time, researchers will grow human lung organoids and use immunogenomic tests to find which airway cells and antigens are being attacked. Insights from mouse models will guide which patients and doses might work best. The combined lab and clinical work aims to reduce airway fibrosis and improve breathing and survival.
Who could benefit from this research
Good fit: Ideal candidates are people who have bronchiolitis obliterans syndrome after an allogeneic hematopoietic cell (stem-cell) transplant.
Not a fit: People without transplant-related BOS, those with other unrelated lung diseases, or those with very advanced, irreversible lung damage may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this could slow or reverse lung scarring, improve breathing, and raise survival for people with post-transplant BOS.
How similar studies have performed: KD025 has shown promising activity for chronic graft-versus-host disease in prior work, but using it specifically to treat BOS is a new application being tested here.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Cutler, Corey S — Dana-Farber Cancer Inst
- Study coordinator: Cutler, Corey S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.